Yahoo Finance • 12 hours ago
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story
Yahoo Finance • 6 days ago
(RTTNews) - Several small-cap names posted sharp gains in Thursday's after-hours session, driven by fresh corporate updates, clinical developments, and strategic pivots. Below are five stocks that stood out for their notable post-close mov... Full story
Yahoo Finance • 2 months ago
Investing.com - Lucid Capital Markets initiated coverage on Ovid Therapeutics Inc (NASDAQ:OVID) with a Buy rating and a $5.50 price target on Wednesday. The target represents significant upside potential for the $38.9 million market cap co... Full story
Yahoo Finance • 3 months ago
LONDON - Solvonis Therapeutics plc (LSE:SVNS) Chairman Dennis Purcell will join a panel discussion at an investor event hosted by Lucid (NASDAQ:LCID) Capital Markets on Thursday, July 17, the clinical-stage biopharmaceutical company announ... Full story
Yahoo Finance • 3 months ago
NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today... Full story
Yahoo Finance • 4 months ago
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on T... Full story
Yahoo Finance • 7 months ago
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appoin... Full story
Yahoo Finance • 7 months ago
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, Presid... Full story
Yahoo Finance • 8 months ago
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will parti... Full story
Yahoo Finance • 2 years ago
Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash runway into 2026 Clinical trials study... Full story
Yahoo Finance • 2 years ago
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid Ovid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway into 2026 while simultaneously reta... Full story
Yahoo Finance • 2 years ago
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today anno... Full story
Yahoo Finance • 2 years ago
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today ann... Full story
Yahoo Finance • 2 years ago
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today ann... Full story
Yahoo Finance • 2 years ago
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today anno... Full story
Yahoo Finance • 2 years ago
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude NicaiseMeg Alexander promoted to Chief Strategy Officer Ovid str... Full story
Yahoo Finance • 2 years ago
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders,... Full story
Yahoo Finance • 2 years ago
Ovid Therapeutics Inc. Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseases Long-term data supporting soticlestat safety, tolerability and seizure-reduction efficacy presen... Full story
Yahoo Finance • 2 years ago
Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton’s expertise in RhoA/ROCK2 signaling pathway to accelerate a series of cli... Full story
Yahoo Finance • 2 years ago
Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studiesSustained reduction in frequency of drop seizures among Lennox-Gastaut patients and convulsive seizures among Dravet patients... Full story